Plasma cardiotrophin-1 as a marker of hypertension and diabetes-induced target organ damage and cardiovascular risk

Medicine (United States)

Volumn 94, Issue 30, 2015, Pages

  Gamella Pozuelo, Luis ^a   Fuentes Calvo, Isabel ^a,b   Gomez Marcos, Manuel A ^b,c   Recio Rodriguez, Jose I ^b,c   Agudo Conde, Cristina ^b,c   Fernandez Martin, Jose L ^a   Cannata Andia, Jorge B ^d   Lopez Novoa, Jose M ^a,b   Garcia Ortiz, Luis ^b,c   Martinez Salgado, Carlos ^a,b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA IBSAL   (Spain)

^c Biomedical Research Institute of Salamanca IBSAL   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CARDIOTROPHIN 1; CREATININE; BIOLOGICAL MARKER; CYTOKINE;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTERIAL WALL THICKNESS; ARTERY INJURY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; ELECTROCARDIOGRAPHY; FEMALE; FIBROSIS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART INJURY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE INJURY; HUMAN; HYPERTENSION; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTIPLE ORGAN FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PULSE PRESSURE; PULSE WAVE; SYSTOLIC BLOOD PRESSURE; TARGET ORGAN; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETIC NEPHROPATHIES; MIDDLE AGED; MORBIDITY; PATHOPHYSIOLOGY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SPAIN; SURVIVAL RATE; TRENDS;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MORBIDITY; PROGNOSIS; PULSE WAVE ANALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPAIN; SURVIVAL RATE;

EID: 84942416542     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001218     Document Type: Article

References (45)

1. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
2. Kelly BB, Narula J, Fuster V. Recognizing global burden of cardiovascular disease and related chronic diseases. Mt Sinai J Med. 2012;79:632-640.
3. Santulli G. Epidemiology of cardiovascular disease in the 21st century: updated numbers and updated facts. J Cardiovasc Dis. 2013;1:1-2.
4. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357.
5. Salomaa V, Riley W, Kark JD, et al. Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation. 1995;91:1432-1443.
6. Liang YL, Shiel LM, Teede H, et al. Effects of blood pressure, smoking, and their interaction on carotid artery structure and function. Hypertension. 2001;37:6-11.
7. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588-2605.
8. Fiorentino TV, Prioletta A, Zuo P, et al. Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr Pharm Des. 2013;19:5695-5703.
9. Pewsner D, Juni P, Egger M, et al. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ. 2007;335:711.
10. Pennica D, King KL, Shaw KJ, et al. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci U S A. 1995;92:1142-1146.
11. Pennica D, Swanson TA, Shaw KJ, et al. Human cardiotrophin-1: protein and gene structure, biological and binding activities, and chromosomal localization. Cytokine. 1996;8:183-189.
12. Lopez-Andres N, Fortuno MA, Diez J, et al. Vascular effects of cardiotrophin-1: A role in hypertension? J Hypertens. 2010;28:1261-1272.
13. Lopez-Andres N, Martin-Fernandez B, Rossignol P, et al. A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. Am J Physiol Heart Circ Physiol. 2011;301:H2372-H2382.
14. Lopez-Andres N, Calvier L, Labat C, et al. Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice. Hypertension. 2013;61:120-129.
15. Gonzalez A, Lopez B, Martin-Raymondi D, et al. Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. J Hypertens. 2005;23:2297-2304.
16. Stejskal D, Ruzicka V. Cardiotrophin-1. Review. Biomed Pap Med Fac Univ Palacky Olomouc Czechoslovakia. 2008;152:9-19.
17. Lopez B, Gonzalez A, Querejeta R, et al. Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: potential diagnostic implications. J Hypertens. 2009;27:418-424.
18. Gonzalez A, Lopez B, Ravassa S, et al. Cardiotrophin-1 in hypertensive heart disease. Endocrine. 2012;42:9-17.
19. Ravassa S, Beloqui O, Varo N, et al. Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients. J Hypertens. 2013;31:587-594.
20. Cottone S, Nardi E, Mule G, et al. Association between biomarkers of inflammation and left ventricular hypertrophy in moderate chronic kidney disease. Clin Nephrol. 2007;67:209-216.
21. Lopez-Andres N, Rousseau A, Akhtar R, et al. Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction. Hypertension. 2012;60:563-573.
22. Natal C, Fortuno MA, Restituto P, et al. Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. Am J Physiol Endocrinol Metab. 2008;294:E52-E60.
23. Moreno-Aliaga MJ, Perez-Echarri N, Marcos-Gomez B, et al. Cardiotrophin-1 is a key regulator of glucose and lipid metabolism. Cell Metab. 2011;14:242-253.
24. Moreno-Aliaga MJ, Romero-Lozano MA, Castano D, et al. Role of cardiotrophin-1 in obesity and insulin resistance. Adipocyte. 2012;1:112-115.
25. Asrih M, Mach F, Quercioli A, et al. Update on the pathophysiological activities of the cardiac molecule cardiotrophin-1 in obesity. Mediators Inflamm. 2013;2013:370715.
26. Lopez B, Gonzalez A, Lasarte JJ, et al. Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J Hypertens. 2005;23:625-632.
27. Lopez B, Castellano JM, Gonzalez A, et al. Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension. Hypertension. 2007;50:977-983.
28. Jougasaki M. Cardiotrophin-1 in cardiovascular regulation. Adv Clin Chem. 2010;52:41-76.
29. Gkaliagkousi E, Gavriilaki E, Nikolaidou B, et al. Association between cardiotrophin 1 levels and central blood pressure in untreated patients with essential hypertension. Am J Hypertens. 2014;27:651-655.
30. Hung HC, Lu FH, Ou HY, et al. Increased cardiotrophin-1 in subjects with impaired glucose tolerance and newly diagnosed diabetes. Int J Cardiol. 2013;169:e33-e34.
31. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-3167.
32. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463-e654.
33. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: The Dublin outcome study. Hypertension. 2005;46:156-161.
34. Gomez-Marcos MA, Recio-Rodriguez JI, Patino-Alonso MC, et al. Protocol for measuring carotid intima-media thickness that best correlates with cardiovascular risk and target organ damage. Am J Hypertens. 2012;25:955-961.
35. Okin PM, Roman MJ, Devereux RB, et al. Electrocardiographic identification of increased left ventricular mass by simple voltageduration products. J Am Coll Cardiol. 1995;25:417-423.
36. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
37. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
38. DAgostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation. 2008;117:743-753.
39. Modesti PA, Agostoni P, Agyemang C, et al. Cardiovascular risk assessment in low-resource settings: A consensus document of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk in Low Resource Settings. J Hypertens. 2014;32:951-960.
40. Bombelli M, Facchetti R, Carugo S, et al. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-ofoffice blood pressure values. J Hypertens. 2009;27:2458-2464.
41. Monserrat L, Lopez B, Gonzalez A, et al. Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. Eur Heart J. 2011;32:177-183.
42. Moreno MU, San Jose G, Pejenaute A, et al. Association of phagocytic NADPH oxidase activity with hypertensive heart disease: A role for cardiotrophin-1? Hypertension. 2014;63:468-474.
43. Rendo-Urteaga T, Garcia-Calzon S, Martinez-Anso E, et al. Decreased cardiotrophin-1 levels are associated with a lower risk of developing the metabolic syndrome in overweight/obese children after a weight loss program. Metabolism. 2013;62:1429-1436.
44. Hage MP, Azar ST. Treating low high-density lipoprotein cholesterol: what is the evidence? Ther Adv Endocrinol Metab. 2014;5: 10-17.
45. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-438.